surmount-1 tirzepatide trial obesity without diabetes on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 SURMOUNT-4 results just published in
Description
The fact that weight loss was only partially responsible for these increases in insulin sensitivity suggests that tirzepatides dual receptor agonism provides additional mechanisms for glycemic control beyond what weight loss alone can give
Tirzepatide represents the first dual incretin receptor agonist available in clinical practice
The results will last as long as you continue to receive your weekly injections
15 mg-2 group: 35.7%
Gallbladder disease -- rapid weight loss raises gallstone risk
Hall KD, Sacks G, Chandramohan D, et al
